PT1399142E - Utilizacao de acetil-l-carnitina em associacao com biotina para o tratamento de doentes com diabetes mellitus insulino-resistente do tipo 2 - Google Patents

Utilizacao de acetil-l-carnitina em associacao com biotina para o tratamento de doentes com diabetes mellitus insulino-resistente do tipo 2

Info

Publication number
PT1399142E
PT1399142E PT02741155T PT02741155T PT1399142E PT 1399142 E PT1399142 E PT 1399142E PT 02741155 T PT02741155 T PT 02741155T PT 02741155 T PT02741155 T PT 02741155T PT 1399142 E PT1399142 E PT 1399142E
Authority
PT
Portugal
Prior art keywords
carnitine
acetyl
association
treatment
resistant
Prior art date
Application number
PT02741155T
Other languages
English (en)
Inventor
Calvani Menotti
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of PT1399142E publication Critical patent/PT1399142E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT02741155T 2001-05-29 2002-05-24 Utilizacao de acetil-l-carnitina em associacao com biotina para o tratamento de doentes com diabetes mellitus insulino-resistente do tipo 2 PT1399142E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re

Publications (1)

Publication Number Publication Date
PT1399142E true PT1399142E (pt) 2006-10-31

Family

ID=11455558

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02741155T PT1399142E (pt) 2001-05-29 2002-05-24 Utilizacao de acetil-l-carnitina em associacao com biotina para o tratamento de doentes com diabetes mellitus insulino-resistente do tipo 2

Country Status (18)

Country Link
US (2) US20040142879A1 (pt)
EP (1) EP1399142B1 (pt)
JP (1) JP4381685B2 (pt)
KR (1) KR20040010666A (pt)
AT (1) ATE333274T1 (pt)
CA (1) CA2448244C (pt)
CY (1) CY1105403T1 (pt)
CZ (1) CZ297743B6 (pt)
DE (1) DE60213237T2 (pt)
DK (1) DK1399142T3 (pt)
ES (1) ES2268053T3 (pt)
HU (1) HUP0400060A2 (pt)
IT (1) ITRM20010294A1 (pt)
MX (1) MXPA03010921A (pt)
PL (1) PL207522B1 (pt)
PT (1) PT1399142E (pt)
SK (1) SK287832B6 (pt)
WO (1) WO2002096410A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE339445T1 (de) * 2000-12-15 2006-10-15 Sigma Tau Ind Farmaceuti Verwendung von l-carnitin als stabilitsator für proteine
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) * 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
SG193655A1 (en) * 2007-03-21 2013-10-30 Sigma Tau Ind Farmaceuti Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
GB201304112D0 (en) * 2013-03-07 2013-04-24 Univ Nottingham Modulation of energy expenditure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes

Also Published As

Publication number Publication date
MXPA03010921A (es) 2004-02-27
EP1399142A1 (en) 2004-03-24
US20040142879A1 (en) 2004-07-22
PL207522B1 (pl) 2010-12-31
EP1399142B1 (en) 2006-07-19
US8053472B2 (en) 2011-11-08
KR20040010666A (ko) 2004-01-31
SK287832B6 (sk) 2011-11-04
WO2002096410A1 (en) 2002-12-05
JP2004532866A (ja) 2004-10-28
PL367630A1 (en) 2005-03-07
ITRM20010294A0 (it) 2001-05-29
CZ20033221A3 (cs) 2004-06-16
US20080269307A1 (en) 2008-10-30
HUP0400060A2 (hu) 2004-04-28
DK1399142T3 (da) 2006-10-30
CA2448244A1 (en) 2002-12-05
CY1105403T1 (el) 2010-04-28
ATE333274T1 (de) 2006-08-15
ES2268053T3 (es) 2007-03-16
DE60213237T2 (de) 2007-08-02
CZ297743B6 (cs) 2007-03-21
JP4381685B2 (ja) 2009-12-09
SK15852003A3 (sk) 2004-04-06
ITRM20010294A1 (it) 2002-11-29
DE60213237D1 (de) 2006-08-31
CA2448244C (en) 2010-11-02

Similar Documents

Publication Publication Date Title
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
TW200640488A (en) Extending time to disease progression or survival in cancer patients
UA85559C2 (en) Aminobenzophenone compounds
BR0115055A (pt) Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos
CY1108808T1 (el) Ενωσεις μοτιλιδης
TW200637535A (en) Aryl sulfones and uses related thereto
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
CY1105403T1 (el) Χρηση της ακετυλο-l-καρνιτινης σε συνδυασμο με τη βιοτινη για τη θepαπεια ασθενων με ινσουλινο-ανθεκτικο σακχαρωδη διαβητη τυπου 2
DK1560575T3 (da) 3,5,3'-triiodthyroninsulfat som thyromimetisk middel og farmaceutiske formuleringer deraf
ITRM20030595A1 (it) Uso della ptx3 o di un suo derivato funzionale da sola o in associazione con tsg6 per il trattamento di patologie degenarative dell'osso o della cartilagine e per il trattamento della infertilita' femminile.
BR0206087A (pt) Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias
BR0007183A (pt) Isonipectoamidas para o tratamento de distúrbios mediados por integrina
ITRM20030178A1 (it) Uso della l-carnitina per il trattamento di patologie cardiovascolari.
MX2008001548A (es) Compuestos antitumorales.
HK1099026A1 (en) Synthesis of spongosine
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
BRPI0412009A (pt) composições compreendendo balaglitazona e outros compostos antidiabéticos
CA2304899A1 (en) New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of non-cardiac origin or with gastro-esophageal reflux disease
BR0211522A (pt) Tratamento de dor crÈnica com 3-arilóxi-3-fenilpropanaminas
BR0214244A (pt) Uso de uma ascomicina
AU2002322806A1 (en) Metformin in the treatment of hyperglycemic conditions
GT200200281A (es) Metodos y composiciones para el tratamiento de patologias respiratorias
ES2187440T3 (es) Utilizacion de orosomucoide en un preparado farmaceutico para el tratamiento de pancreatitis aguda.
ITRM20020181A1 (it) Medicamento utile per il trattamento della fatica in pazienti affettida sclerosi multipla.
ITMI20031184A1 (it) Composizione per il trattamento della pelle particolarmente